Genomic amplification of MET is frequently observed in human cancers, including non-small cell lung cancer (NSCLC), where it occurs in 25–75% of cases, depending on the study and criteria used to define overexpression [36,37]. This evidence concerns the gene MET and non-small cell lung carcinoma.